Dose-Related Safety and Immunogenicity of a Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine in Elderly Adults

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine.

Methods

In a randomized, double-blind trial conducted in 399 adults ≥65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 μg, 45 μg, or 135 μg of each HA.

Results

Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 μg or 135 μg of each HA.

Conclusions

Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.

Related Topics

    loading  Loading Related Articles